18f-av-1451
18f-av-1451 - Related Videos
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
0 Views •
Cited by 1 •
2025
This protocol describes the use of 18F-AV-1451 PET/MRI to reveal tau pathology and neurodegeneration, aiding neurologists in diagnosing Alzheimer's disease, assessing its severity, and gaining insights into its progression and underlying pathological mechanisms.
08:53
The Arteriovenous (AV) Loop in a Small Animal Model to Study Angiogenesis and Vascularized Tissue Engineering
0 Views •
Cited by 38 •
2016
We describe a microsurgical approach for the generation of an arteriovenous (AV) loop as a model for analyzing vascularization in vivo in an isolated and well-characterized environment. This model is not only useful for the investigation of angiogenesis, but is also optimally suited for engineering axially vascularized and transplantable tissues.
09:57
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
0 Views •
Cited by 15 •
2017
We have developed a modular high-throughput screening system for discovering novel compounds against Mycobacterium tuberculosis, targeting intracellular and in-broth growing bacteria as well as cytotoxicity against the mammalian host cell.
08:20
Cell Block Preparation from Cytology Specimen with Predominance of Individually Scattered Cells
0 Views •
Cited by 67 •
2009
Shidham's method for preparation of cell blocks with AV-marker from cytology specimens containing individually scattered cells and small cell groups.
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
0 Views •
2025
Overtreatment is often administered to patients with low-risk prostate cancer; super-active surveillance can help avoid such overtreatment.
FAQs
Regional retention provides a spatial readout of where tracer-associated signal accumulates in the brain. Investigators examine its distribution across regions rather than treating the scan as a single global value. This pattern can be compared with tau burden and cognitive decline in Alzheimer’s disease research, helping relate regional pathology to clinical change.
Off-target binding can contribute to tracer retention that does not reflect the intended paired helical filament tau signal. For that reason, researchers interpret 18F-AV-1451 scans cautiously rather than assuming every region of increased uptake represents equivalent neurofibrillary pathology. This consideration is especially important when comparing regional findings or evaluating disease-related patterns.
Tracer uptake can differ among neurodegenerative disorders, so the same imaging pattern should not automatically be assigned the same pathological meaning in every disease. Interpretation must account for disease-specific differences in uptake alongside the possibility of off-target binding. This context helps researchers evaluate whether regional retention is consistent with the disorder under study.
The workflow begins with intravenous administration of the fluorine-18-labeled tracer, followed by its passage across the blood-brain barrier. PET imaging then records regional tracer retention and distribution in the living brain. Researchers use the resulting map to examine tau-related patterns, compare brain regions, and connect imaging findings with clinical or pathological measures.
In Alzheimer’s disease studies, flortaucipir PET helps assess tau burden and its distribution across the brain. Researchers can examine how these imaging measures relate to disease progression and cognitive decline over the course of investigation. This makes the tracer useful for studying relationships between pathological change and clinical outcomes in living participants.
Clinical trials can use 18F-AV-1451 to evaluate participants in relation to tau pathology and to examine imaging changes alongside disease progression. Its regional retention data provide a way to study whether pathological patterns correspond with clinical measures during a trial. However, interpretation still requires attention to off-target binding and disease-specific uptake differences.